Clinical Trial Update: Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery [Phase 2]

View source ↗

Summary

A Phase 2 study comparing ipilimumab with or without sargramostim in patients with unresectable Stage III or Stage IV melanoma, with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Leukine (sargramostim)
• Yervoy (ipilimumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Melanoma, Metastatic Melanoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2015-04-02